中文摘要：

目的研究浸润性导管癌分子分型与预后的关系。方法回顾性分析2008年11月-2009年11月杭州市中医院收治的乳腺浸润性导管癌患者87例，根据WHO标准规定对患者进行免疫学分型，对患者术后随访3年。观察各型患者治疗后的肿瘤复发和淋巴结转移率及3年内的生存率情况。结果Luminal A型患者在3年内的生存率最高，为86．96％，Triple-Negative型的生存率最低，为60．00％；Triple-Negative型淋巴结复发、转移时间及淋巴结复发、转移率较其他三类分型高，差异有统计学意义（P〈0．05）。结论乳腺浸润性导管癌分子分型与预后关系密切，且分型不同预后情况不同，其中LuminalA型预后最好。

英文摘要：

Objective To study the relationship between invasive ductal carcinoma molecular typing and prognosis. Methods 87 cases of infiltrating ductal breast cancer patients in Hangzhou Hospital of Traditional Chinese Medicine from November 2008 to November 2009 were analyzed retrospectively. According to the WHO standard requirements, patients were performed immune typing. In postoperation, patients were followed up for 3 years. The tumor recurrence and lymph node metastasis rate and three years survival situation of various types of patients after treatment were ob- served. Results Patients of Luminal A had the highest survival rate in three years, which was 86.96%, Triple-Negative type of patients had the lowest survival rate, which was 60.00%; the lymph node recurrence, time of transfer and lymph node recurrence, metastasis rate of Triple-Negative type were higher than the other three types of parting, the differences were statistically significant （P 〈 0.05）. Conclusion The molecular typing of infiltrating ductal breast can- cer has close relationship with prognosis, and different types have different outcomes of prognosis, of which, Luminal A has the best prognosis.